therapy with mitoxantrone (8 mg/m 2 for 5 days), VP-16 (100 mg/m 2 for 3 days), carboplatin (200 mg/m 2 for 2 days) and Ara-C (500 mg/m 2 /12 h for 2 days) were given. After A 40-year-old male weighing 90 kilograms was diagnosed with acute myeloblastic leukaemia M5a which the second cycle the bone marrow remained aplastic and infiltrated with leukaemia cells, and the patient required was resistant to chemotherapy. Neither a related nor an unrelated HLA-compatible bone marrow donor could periodic red cell and platelet transfusions. Neither a related nor an unrelated HLA-compatible bone be found. A unit of cord blood was found with an HLA compatibility of four out of six loci, and was infused marrow donor could be found. In June 1996 a unit of cord blood from the Milano Cord Blood Bank was available, after conditioning with cyclophosphamide, total body irradiation and antilymphocyte globulin. The infused with an HLA compatibility of four out of six loci using high resolution molecular typing for DR locus (Table 1) . cord blood had 0.98 ؋ 10 7 nucleated cells per kilogram.
/l, and there was total chimerism of the first cord blood unit infused. Two weeks later was thawed and infused on day 0, according to the technical procedure described by Rubinstein et al. 1 The viable leukocyte counts decreased progressively and the patient died of a disseminated fungal infection. We disnucleated cells after thawing were 0.98 ϫ 10 7 per kilogram (Table 2) . Prophylaxis against graft-versus-host disease cuss the importance of the number of nucleated cells per kilogram of body weight infused, and the role of consisted of intravenous cyclosporine (5 mg/kg/day). Granulocyte colony-stimulating factor (5 g/kg/day) was given intensive immunosuppression in engraftment of cord blood transplantations in adults.
beginning on day 7. The patient's course after transplanKeywords: cord blood transplant; adult; immunosuppression Table 1 Compatibility between the patient and the cord blood units 
/CD56
ϩ ), and natural killer activity, measured in a standard cytotoxicity assay, 2 was 26 ϫ 10 Ϫ3 LU/10 6 MNC, data consistent with early engraftment. 3 Red cell and platelet transfusions were still required. At that time, the bone marrow aspirate showed megaloblastic erythroid nests and myeloid nests with predominance of promyelocytes and myelocytes, and the megakaryocyte lineage was not present. Antibiotics were stopped and the chest X-ray returned to normal. There were no signs of graft-versus-host disease. On day 71 (30 post-second transplant) the leukocyte count began to decrease, reaching 0.5-0.6 ϫ 10 9 /l in 1 week. Granulocyte colony-stimulating factor dose was increased to 15 g/kg. than the previous aspirate and did not show leukaemic relapse. On day 89 (48 post-second transplant) the patient developed high fever, and imipenem (500 mg/6 h) and amitation was complicated by multiple bacteremic episodes caused by Enterobacter cloacae and multiresistant Enterokacin (500 mg/12 h) were started. Escherichia coli was isolated in blood cultures. He persisted with fever and a bacter aerogenes, requiring intravenous treatment with meropenem (2 g/8 h), amikacin (500 mg/6 h) and ciproprogressive respiratory distress syndrome appeared. Vancomycin (500 mg/6 h) was added. On day 97 (56 post-second floxacin (750 mg/12 h). Bone marrow aspirates on days 21 and 34 were aplastic, and the peripheral leukocyte count transplant) the patient developed multiple organ failure and died. Necropsy findings were consistent with systemic was below 0.1 ϫ 10 9 /l. He was considered to have graft failure according to the definition in our transplantation mycosis infiltrating myocardium, pericardium, lungs and oesophagus. Bone marrow was aplastic but there was no protocol.
A second unit of cord blood was found in the Barcelona evidence of leukaemia. Chimerism was evaluated by amplification of the hyperCord Blood Bank with an HLA compatibility of four out of six using high resolution typing for DR locus (Table 1) .
variable regions of DNA using polymerase chain reaction (PCR). 4 It showed a mixed chimera on day 34 after the first The unit contained 1.59 ϫ 10 7 nucleated cells per kilogram ( Table 2 ). The patient received antilymphocyte globulin transplant and a total chimera of the first cord blood on day 58 (17 post-second transplant) (Figure 1 ). The sample on (Merieux, 15 mg per 5 kg per day for 3 days) before infusion. The second cord blood unit was thawed 1 and day 73 (32 post-second transplant) was not good enough to provide information on the chimera of the second cord We did not find any cause for losing the graft, such as cytomegalovirus infection, toxic drugs, or graft-versus-host blood.
disease. Our patient presented two HLA disparities with the cord blood unit infused. The risk of graft failure seems to be higher when there are mismatches for class I HLA Discussion alleles. 16 The low number of nucleated cells infused could have also played a role. Also, our patient had active disease Umbilical cord blood has recently emerged as an alternative source of haematopoietic stem cells. 5 In 1989 the first sucwhen he received the transplant, and although leukaemic cells were no longer detected, an injured microenvironment cessful transplantation of cord blood was performed in a 6-year-old child with Fanconi's anaemia. 6 Since that time could have been a factor in the failure of engraftment. 17 We believe that unrelated umbilical cord blood transplanadditional transplants with related cord blood have been performed in children with HLA-matched siblings. 7 The tation in adults is a promising procedure, but the minimal dose of nucleated cells infused should be established. It is possibility of transplanting cord blood from unrelated donors has been studied 8 and cord blood banks have been possible that more immunosuppressive conditioning regimens could improve the outcome of these patients. established.
1,9 The quality of lymphocytes could permit transplantation of units disparate at one to three HLA alleles due to reduced risk of graft-versus-host disease. 7 Results of the first unrelated transplants have been
